3 / 25
Page 55
Notes:
conferenceseries
.com
Volume 8, Issue 3(Suppl)
J Allergy Ther, an open access journal
ISSN: 2155-6121
Allergy-Clinical Immunology 2017
September 07-08, 2017
September 07-08, 2017 | Edinburgh, Scotland
ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY
11
th
International Conference on
Therapeutic use of microRNAs to prevent and control allergic rhinosinusitis
Gilbert Glady
European Bio Immun(G)en Medicine Association, France
I
nflammatory upper airway diseases, particularly chronic rhinosinusitis (CRS) and allergic rhinitis (AR), have a high
worldwide prevalence. CRS and AR involve sustained and exaggerated inflammation that is associated with marked changes
in gene and protein expression under tight regulation. MicroRNAs represent one of the fundamental epigenetic regulatory
mechanisms used by cells that can mediate posttranscriptional gene silencing of target genes. As fine tuning regulators of gene
expression, miRNAs are involved in diverse biologic processes, including cell proliferation, apoptosis, and differentiation,
organ development, metabolism, stress responses, and signal transduction. Emerging evidence implicates an involvement of
miRNAs in shaping the inflammation pattern in upper airways. Studies regarding the roles of miRNAs in allergic diseases have
multiplied during the last 4 years, and the functions of miRNAs in the regulation and pathogenesis of these diseases are more
and more better characterized. Recently, miRNAs have been shown to be detectable in cell-free body fluids such as serum
and plasma samples. The circulating miRNAs are protected from blood RNAses either by existing in cell membrane-derived
vesicles such as exosomes or by forming a complex with lipid-protein carriers such as high-density lipoprotein. So it becomes
possible to use such kind of molecules for a therapeutic purpose, and that is what achieve the Bio Immun(G)en Medicine –
BI(G)MED – by introducing high diluted microRNAs in nano compounds looking for a fine regulation in different upper
airways diseases with an allergic etiology.
Biography
Gilbert Glady has completed his MD from Strasbourg University of Medicine and Postdoctoral studies from Besançon and Paris-Nord Universities of Medicine.
He got an expertise in immunology and immunogenetics during all these years and developed interest for alternative medicines. So in 2010, he became Creator
of the BI(G)MED method and Director of EBMA, the European association for training the medical profession at the BI(G)MED. He has participated in numerous
international congresses in the field of immuno-allergology, infectiology and oncology with posters and oral presentations.
dr.glady68@gmail.comGilbert Glady, J Allergy Ther 2017, 8:3(Suppl)
DOI: 10.4172/2155-6121-C1-006